Zydus Lifesciences: Co. To Buy Assertio Holdings Listed On NASDAQ For ₹1,592 Cr ($193 Million) In Cash At $23.50 Per Share, Enhancing Its Position In The U.S. Specialty And Pain Management Pharmaceuticals Market. - BL

 14 May 2026 09:04 AM

Zydus Lifesciences: Co. To Buy Assertio Holdings Listed On NASDAQ For ₹1,592 Cr ($193 Million) In Cash At $23.50 Per Share, Enhancing Its Position In The U.S. Specialty And Pain Management Pharmaceuticals Market. - BL

Zydus Lifesciences: Subsidiary Zydus Worldwide DMCC Set to Buy Entire Stake in Nasdaq-Listed Assertio Holdings for $23.50 Per Share, Amounting to $166.4 Million

 13 May 2026 08:41 PM

Zydus Lifesciences: Subsidiary Zydus Worldwide DMCC Set to Buy Entire Stake in Nasdaq-Listed Assertio Holdings for $23.50 Per Share, Amounting to $166.4 Million

Zydus Lifesciences: Board Meeting Planned To Discuss Share Buyback Proposal On May 19, 2026.

 13 May 2026 04:00 PM

Zydus Lifesciences: Board Meeting Planned To Discuss Share Buyback Proposal On May 19, 2026.

Zydus Lifesciences: Enters Agreement With Lupin To Co-Market Semaglutide Injection In India, Zydus Will Promote It As Semaglyntm, Mashematm, And Altermetm, While Lupin Will Sell It As Semanext And Livarise.

 17 Mar 2026 12:01 PM

Zydus Lifesciences: Enters Agreement With Lupin To Co-Market Semaglutide Injection In India, Zydus Will Promote It As Semaglyntm, Mashematm, And Altermetm, While Lupin Will Sell It As Semanext And Livarise.